293 related articles for article (PubMed ID: 27135134)
21. Prescription of methylphenidate to children and youth, 1990-1996.
Miller AR; Lalonde CE; McGrail KM; Armstrong RW
CMAJ; 2001 Nov; 165(11):1489-94. PubMed ID: 11762572
[TBL] [Abstract][Full Text] [Related]
22. Physician practices to prevent ADHD stimulant diversion and misuse.
Colaneri N; Keim S; Adesman A
J Subst Abuse Treat; 2017 Mar; 74():26-34. PubMed ID: 28132697
[TBL] [Abstract][Full Text] [Related]
23. Physician Office Visits for Attention-deficit/Hyperactivity Disorder in Children and Adolescents Aged 4-17 Years: United States, 2012-2013.
Albert M; Rui P; Ashman JJ
NCHS Data Brief; 2017 Jan; (269):1-8. PubMed ID: 28135186
[TBL] [Abstract][Full Text] [Related]
24. Assessing the impact of the extended-release/long-acting opioid an-algesics risk evaluation and mitigation strategies on opioid prescrip-tion volume.
Divino V; Cepeda MS; Coplan P; Maziere JY; Yuan Y; Wade RL
J Opioid Manag; 2017; 13(3):157-168. PubMed ID: 28829517
[TBL] [Abstract][Full Text] [Related]
25. Management of Attention-Deficit/Hyperactivity Disorder by Developmental-Behavioral Pediatricians: A DBPNet Study.
Harstad E; Blum N; Gahman A; Shults J; Chan E; Barbaresi W
J Dev Behav Pediatr; 2016 Sep; 37(7):541-7. PubMed ID: 27429355
[TBL] [Abstract][Full Text] [Related]
26. New chronic disease medication prescribing by nurse practitioners, physician assistants, and primary care physicians: a cohort study.
Marcum ZA; Bellon JE; Li J; Gellad WF; Donohue JM
BMC Health Serv Res; 2016 Jul; 16():312. PubMed ID: 27464570
[TBL] [Abstract][Full Text] [Related]
27. Assessment of Prescriber and Pharmacy Shopping Among the Family Members of Patients Prescribed Opioids.
Chua KP; Brummett CM; Conti RM; Haffajee RL; Prosser LA; Bohnert ASB
JAMA Netw Open; 2019 May; 2(5):e193673. PubMed ID: 31074819
[TBL] [Abstract][Full Text] [Related]
28. Indication and use of drug products used to treat attention-deficit/hyperactivity disorder: a cross-sectional study with inference on the likelihood of treatment in adulthood.
Brinker A; Mosholder A; Schech SD; Burgess M; Avigan M
J Child Adolesc Psychopharmacol; 2007 Jun; 17(3):328-33. PubMed ID: 17630866
[TBL] [Abstract][Full Text] [Related]
29. Prescription patterns for children with juvenile idiopathic arthritis in Michigan Medicaid: a comparison by prescriber type.
Riebschleger MP; Van Mater HA; Cohn LM; Clark SJ
Pediatr Rheumatol Online J; 2014; 12():38. PubMed ID: 25228851
[TBL] [Abstract][Full Text] [Related]
30. Trends in Antipsychotic Prescribing in Medicaid-Eligible Youth.
Edelsohn GA; Karpov I; Parthasarathy M; Hutchison SL; Castelnovo K; Ghuman J; Schuster JM
J Am Acad Child Adolesc Psychiatry; 2017 Jan; 56(1):59-66. PubMed ID: 27993230
[TBL] [Abstract][Full Text] [Related]
31. Primary care providers' prescribing practices of opioid controlled substances.
Shields LB; Nasraty S; Bell AD; Vinayakan AN; Gudibanda RS; Hester ST; Honaker JT
J Opioid Manag; 2016; 12(6):397-403. PubMed ID: 28059432
[TBL] [Abstract][Full Text] [Related]
32. Influence of Age, Gender, and Living Circumstances on Patterns of Attention-Deficit/Hyperactivity Disorder Medication Use in Children and Adolescents With or Without Intellectual Disabilities.
Osunsanmi S; Turk J
J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):828-834. PubMed ID: 26982546
[TBL] [Abstract][Full Text] [Related]
33. The Geographic Impact of Buprenorphine Expansion to Nurse Practitioner Prescribers in Oregon.
Klein TA; Geddes J; Hartung D
J Rural Health; 2022 Jan; 38(1):112-119. PubMed ID: 33188544
[TBL] [Abstract][Full Text] [Related]
34. Variations in prescription drug monitoring program use by prescriber specialty.
Sun BC; Lupulescu-Mann N; Charlesworth CJ; Kim H; Hartung DM; Deyo RA; John McConnell K
J Subst Abuse Treat; 2018 Nov; 94():35-40. PubMed ID: 30243415
[TBL] [Abstract][Full Text] [Related]
35. Potentially Preventable Hospitalizations in Medicare Patients With Diabetes: A Comparison of Primary Care Provided by Nurse Practitioners Versus Physicians.
Kuo YF; Chen NW; Baillargeon J; Raji MA; Goodwin JS
Med Care; 2015 Sep; 53(9):776-83. PubMed ID: 26270826
[TBL] [Abstract][Full Text] [Related]
36. Health care supply and county-level variation in attention-deficit hyperactivity disorder prescription medications.
Bruckner TA; Hodgson A; Mahoney CB; Fulton BD; Levine P; Scheffler RM
Pharmacoepidemiol Drug Saf; 2012 Apr; 21(4):442-9. PubMed ID: 22021031
[TBL] [Abstract][Full Text] [Related]
37. Treatment of Young People With Antipsychotic Medications in the United States.
Olfson M; King M; Schoenbaum M
JAMA Psychiatry; 2015 Sep; 72(9):867-74. PubMed ID: 26132724
[TBL] [Abstract][Full Text] [Related]
38. The impact of CARA mandates on nurse practitioner controlled substance prescribing in Oregon: a cohort study.
Klein TA; Hartung D; Markwardt S
Subst Abuse Treat Prev Policy; 2022 Jan; 17(1):5. PubMed ID: 35101077
[TBL] [Abstract][Full Text] [Related]
39. Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in quebec.
Lachaine J; De G; Sikirica V; Van Stralen J; Hodgkins P; Yang H; Heroux J; Ben Amor L
Can J Psychiatry; 2014 Nov; 59(11):597-608. PubMed ID: 25565476
[TBL] [Abstract][Full Text] [Related]
40. The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children.
Matone M; Localio R; Huang YS; dosReis S; Feudtner C; Rubin D
Health Serv Res; 2012 Oct; 47(5):1836-60. PubMed ID: 22946905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
